Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Net Margin (2018 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Net Margin for 15 consecutive years, with 75.06% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 14767.0% to 75.06% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 46.42% through Dec 2025, up 6502.0% year-over-year, with the annual reading at 46.42% for FY2025, 4884.0% up from the prior year.
  • Net Margin hit 75.06% in Q4 2025 for Ligand Pharmaceuticals, down from 101.57% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 101.57% in Q3 2025 to a low of 93.64% in Q1 2025.
  • Historically, Net Margin has averaged 5.04% across 5 years, with a median of 6.99% in 2021.
  • Biggest five-year swings in Net Margin: plummeted -6057bps in 2021 and later surged 14767bps in 2025.
  • Year by year, Net Margin stood at 3.94% in 2021, then plummeted by -49bps to 5.86% in 2022, then soared by 35bps to 3.79% in 2023, then crashed by -1818bps to 72.62% in 2024, then soared by 203bps to 75.06% in 2025.
  • Business Quant data shows Net Margin for LGNDZ at 75.06% in Q4 2025, 101.57% in Q3 2025, and 10.18% in Q2 2025.